Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas

J Endocrinol Invest. 2004 Apr;27(4):311-7. doi: 10.1007/BF03351054.

Abstract

Preoperative follicular lesion characterisation represents an unsolved diagnostic problem in thyroid nodular disease. Although fine-needle aspiration biopsy is the most reliable preoperative diagnostic procedure, it shows inherent limitations in differentiating adenoma from follicular carcinoma and, sometimes, follicular variants of papillary carcinoma. Galectin-3 cytoplasmic neoexpression has been proposed as a peculiar feature of thyroid malignant cells, easily detectable in cytological and histological samples. The aim of this study was to re-evaluate the galectin-3 expression in a large sample of thyroid lesions using an immunohistocytochemical biotin-free detection system and a specific anti-human-galectin-3 monoclonal antibody in order to avoid the interference of technical factors, a cause of conflicting results recently reported by some authors. We analysed galectin-3 expression of 39 follicular carcinomas, 26 papillary carcinomas, and 105 adenomas in both cell-block samples and their histological counterparts. All cell-block and histological papillary carcinoma samples showed high levels of galectin-3 immunoreactivity. Thirty-four follicular carcinomas were positive, whereas 5 were negative in cell-blocks but positive in their histological counterparts. Twelve out of 105 adenomas expressed galectin-3 in cell-blocks and histological samples. The diagnostic accuracy of preoperative galectin-3 evaluation in adenomas vs follicular carcinomas was 90.0%. Galectin-3 expression was also investigated in 22 minimally-invasive follicular carcinomas. All of them showed galectin-3 immunoreactivity in both cytological and histological specimens with the exception of two cases, where galectin-3 positivity was observed only in the surgical material. The routine correct use of galectin-3, by increasing the diagnostic accuracy of conventional cytology, improves the management of thyroid nodules and can lead to a sensitive reduction of useless thyroid surgeries.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Follicular / chemistry
  • Adenocarcinoma, Follicular / diagnosis*
  • Adenocarcinoma, Follicular / pathology
  • Adenoma / chemistry
  • Adenoma / diagnosis
  • Adenoma / pathology
  • Antibodies, Monoclonal
  • Biomarkers, Tumor / analysis*
  • Biopsy, Fine-Needle
  • Carcinoma, Papillary / chemistry
  • Carcinoma, Papillary / diagnosis
  • Carcinoma, Papillary / pathology
  • Cell Nucleus / chemistry
  • Cytoplasm / chemistry
  • Diagnosis, Differential
  • Galectin 3 / analysis*
  • Humans
  • Immunohistochemistry
  • Preoperative Care
  • Retrospective Studies
  • Sensitivity and Specificity
  • Thyroid Neoplasms / chemistry
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / pathology
  • Thyroid Nodule / pathology
  • Thyroid Nodule / surgery*

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • Galectin 3